Orforglipron

LY3502970

Add to protocol

Build with Orforglipron

Compare prices

Pharmacies & vendors

Calculate dosing

Reconstitution

Overview

Orforglipron is Eli Lilly's oral non-peptide GLP-1 receptor agonist. Small molecule, no food restrictions, currently in Phase III for obesity and T2D.

Mechanism of Action

Selective GLP-1 receptor agonism via a non-peptide small-molecule scaffold that allows oral bioavailability without the fasting requirements of semaglutide tablets.

Research Summary

Phase II showed ~14.7% weight loss at 36 weeks. Phase III ACHIEVE / ATTAIN programs ongoing; approval expected 2026.

Dosing Information

Typical Dose

12–36 mg

Frequency

Daily

Route

Oral

Notes

No food restriction. Research chemical outside clinical trials.

Reported Side Effects

Nausea
Vomiting
Diarrhea
Constipation

Contraindications

Personal or family history of medullary thyroid carcinoma
Pregnancy

Track your Orforglipron protocol

Build a protocol with Orforglipron, schedule blood work for key biomarkers, and track your results.

Build Protocol with Orforglipron

This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.